Clinical studies have shown improved cardiovascular outcomes, including reduced hospitalization and heart failure symptoms in patients with heart failure, stroke, or diabetes who received GLP-1 analogues; however, the mechanisms involved in these beneficial effects are not clear [11,12,13,14,15]. This evidence concerns the gene GCG and heart failure.